A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is characterised by progressive pulmonary vascular remodelling. Here, Arnold et al. develop a therapeutic antibody targeting osteoprotegerin and find it attenuates pulmonary vascular remodelling in multiple rodent models of PAH, alone or in combination with stan...
Guardado en:
Autores principales: | Nadine D. Arnold, Josephine A. Pickworth, Laura E. West, Sarah Dawson, Joana A. Carvalho, Helen Casbolt, Adam T. Braithwaite, James Iremonger, Lewis Renshall, Volker Germaschewski, Matthew McCourt, Philip Bland-Ward, Hager Kowash, Abdul G. Hameed, Alexander M. K. Rothman, Maria G. Frid, A. A. Roger Thompson, Holly R. Evans, Mark Southwood, Nicholas W. Morrell, David C. Crossman, Moira K. B. Whyte, Kurt R. Stenmark, Christopher M. Newman, David G. Kiely, Sheila E. Francis, Allan Lawrie |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fbbe9cf6fb44471db21ebf04ce2094b6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Expression of osteoprotegerin in placenta and its association with preeclampsia.
por: Pei Shen, et al.
Publicado: (2012) -
Effect of Lovastatin on Serum Osteoprotegerin Level in Type 2 Diabetic Nephropathy
por: N Nezami,, et al.
Publicado: (2012) -
Osteoprotegerin-dependent M cell self-regulation balances gut infection and immunity
por: Shunsuke Kimura, et al.
Publicado: (2020) -
Osteoprotegerin, pericytes and bone-like vascular calcification are associated with carotid plaque stability.
por: Jean-Michel Davaine, et al.
Publicado: (2014) -
Osteoprotegerin is a marker of cardiovascular mortality in patients with chronic kidney disease stages 3–5
por: Gustavo Lenci Marques, et al.
Publicado: (2021)